reports
Elbit Medical Technologies Limited: 1 director sold
A director at Elbit Medical Technologies Limited sold 4,693,423 shares at 1.500ILS and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
- Sean Conroy
Elbit Medical Technologies - Gamida hits on Phase III
Elbit Medical’s holding Gamida Cell recently reported data from its 125-patient Phase III study of omidubicel in patients with haematological malignancies undergoing bone marrow transplants. The median time to neutrophil engraftment was 12 days for omidubicel patients compared to 22 days for those receiving standard umbilical cord blood (p
- Sean Conroy
Elbit Medical Technologies - Large portion of InSightec stake sold
Elbit Medical recently completed the sale of most of its stake in InSightec for $102.2m, at a $702m valuation for the company. In March, InSightec announced a Series F funding round that is being led by current investor, Koch Disruptive Technologies, which will raise an additional $150m for InSightec. The post-money valuation for InSightec would be $1.3bn fully diluted. Following these transactions, Elbit Medical now has a stake of approximately 3.3% of InSightec (2.8% on a fully diluted basis) ...
- Sean Conroy
Elbit Medical Technologies - Selling most of its InSightec stake
Elbit Medical recently signed an agreement to sell most of its stake in InSightec for $102m at a $702m valuation for the company, leaving Elbit Medical with approximately 4.7% of InSightec (the company estimates approximately 3.7% on a fully diluted basis). At the end of Q319, Elbit Medical owned 22% of InSightec and 18% on a fully diluted basis. Completion of the transaction is subject to Elbit Medical shareholder approval and other conditions. The company expects to use the proceeds of this tr...
- Sean Conroy
Elbit Medical Technologies - H119 results
Elbit Medical Technologies’ two portfolio investments continue to make progress. InSightec recently received both FDA approval and a CE mark for ExAblate Neuro compatible with the SIGNA Premier MRI system from GE Healthcare as the two companies work on improving incisionless brain surgery. Gamida Cell recently completed a $40m follow-on offering and expects to complete enrolment of the Phase III for NiCord (now called omidubicel) by the end of the year, with data in H120.
- Maxim Jacobs
Elbit Medical Technologies - Full-year financial results
Elbit Medical Technologies’ two portfolio investments continue to advance on multiple fronts. InSightec recently completed its compatibility project with Siemens MR scanners and its ExAblate Neuro units, which lends the opportunity to expand its presence in the global MR market. According to Gamida Cell, its cash balance should fund its operations through the top-line readout of its Phase III study of NiCord, which is expected in H120.
- Maxim Jacobs
Elbit Medical Technologies - Another FDA approval and a US IPO
Elbit Medical Technologies’ two portfolio investments continue to advance. Notably, Gamida Cell announced a $53m IPO on Nasdaq in late October and presented NiCord data at the American Society of Hematology (ASH) annual meeting in December. InSightec reported record revenues for Q318 and received FDA approval for ExAblate Neuro compatibility with Siemens’ magnetic resonance (MR) scanners.
- Maxim Jacobs
Elbit Medical Technologies - Portfolio progress continues
Elbit Medical Technologies’ portfolio of investments continues to demonstrate progress on multiple fronts. InSightec is gaining ground on the reimbursement front, with Medicare providing coverage for beneficiaries in a total of 16 US states for the use of magnetic resonance imaging and high-intensity focused ultrasound (MRgFUS) for essential tremor (ET) treatment. Moreover, Gamida Cell recently announced that the FDA has granted NiCord orphan drug designation for the treatment of haematopoieti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.